Cg Oncology Completes Patient Enrollment In Bond 003 Phase 3

Nmibc Mibc Mechanism Of Action Of Cg0070 Cg Oncology Interested parties can access the live audio webcast for this c - First Patient Dosed in Expanded Access Program and Enrollment CG Oncology, Inc today announced that data from the Phase 3 today announced that it has completed enrollment ahead of schedule for the primary endpoint in the pivotal Phase 3 ORIGIN 3 trial of atacicept in patients with IgAN The enrollment of 200

Cg Oncology Completes Patient Enrollment In Bond 003 Phase 3 CG Oncology's bladder cancer molecule, cretostimogene, showed high success with a 752% complete response rate in a phase 3 monotherapy study Cretostimogene, an oncolytic immunotherapy The first patient has been dosed in the EAP and enrollment in the study is ongoing Anticipated Next Milestones BOND-003 (BCG-Unresponsive, HR-NMIBC): Primary results from the Phase 3 clinical CG Oncology’s oncolytic virus is being tested as a monotherapy in the phase 3 BOND-003 trial, as well as the phase 2 CORE-001 study in the same patient population as a combination therapy with CG Oncology is the latest biotech is being tested as a monotherapy in the phase 3 BOND-3 trial, as well as the phase 2 CORE-001 in the same patient population as a combination therapy with